Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Replay
The Medicines Company Conference Call to Discuss Clinical Trial Results of ABP-700 and MDCO-216
06/02/15 at 8:30 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at Jefferies 2015 Global Healthcare Conference
06/01/15 at 10:00 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at Bank of America Merrill Lynch 2015 Health Care Conference
05/14/15 at 10:00 a.m. PT
Webcast ImageWebcast - Replay
Q1 2015 The Medicines Company Earnings Conference Call
05/05/15 at 8:30 a.m. ET
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Download Documentation Jefferies 2015 Global Healthcare Conference
Download Documentation JP Morgan Conference Presentation
Download Documentation Nov. 5th 2014 Investor & Analyst Day
Download Documentation The Medicines Company Acquisition of Tenaxis Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$31.39
Change (%) Stock is Up 0.99 (3.26%)
Volume1,626,630
Data as of 07/31/15 4:15 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
07/29/15The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results
Commercial resources focused on new product launches R&D investment in potential blockbusters continues Company contracts with Sandoz for launch of authorized generic bivalirudin (Angiomax) Company exploring strategic-partnering options to accelerate business development and unlock value PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 29, 2015-- The Medicines Company (NASDAQ:MDCO) today... 
Printer Friendly Version
07/13/15The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 2015
Conference Call to be held at 8:30 a.m. Eastern Time PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 13, 2015-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, July 29th at 8:30 a.m. Eastern Time to discuss second quarter financial results, operational developments and outlook for 2015. The conference call will be available via phone and webcast. The dial-in information is listed below: ... 
Printer Friendly Version
07/09/15The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 9, 2015-- The Medicines Company (NASDAQ:MDCO) today announced an agreement with Sandoz Inc. for the distribution of an authorized generic of ANGIOMAX® (bivalirudin) for injection in the United States. “Bivalirudin has become a foundation anti-thrombin for patients undergoing PCI under The Medicines Company’s fifteen-year leadership in the cath lab,” said Glenn Sblendorio, President and Chief Financial ... 
Printer Friendly Version
07/02/15Federal Circuit Rules Against The Medicines Company in Angiomax® (bivalirudin) Patent Litigation
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 2, 2015-- The Medicines Company (NASDAQ:MDCO) announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the Company in its Angiomax® (bivalirudin) patent litigation with Hospira, Inc. In its ruling today, the Federal Circuit held that U.S. Patent Nos. 7,582,727 (the ‘727 patent) and 7,598,343 (the ‘343 patent) are invalid. On March 31, 2014, the U.S. District Court of Delaw... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.